What is the first-line oral antibiotic for treating minor MSSA infections?

The first-line oral antibiotic for treating minor infections caused by methicillin-sensitive Staphylococcus aureus (MSSA) is dicloxacillin. This antibiotic is a penicillinase-resistant penicillin, specifically designed to combat β-lactamase producing organisms, making it effective against MSSA.

Dicloxacillin is particularly well-suited for outpatient treatment of uncomplicated skin and soft tissue infections frequently caused by MSSA. Its oral bioavailability and targeted activity help ensure effective treatment of such infections while minimizing the risk of antibiotic resistance.

Other options, while useful for various infections or specific clinical scenarios, do not match dicloxacillin's effectiveness for treating minor MSSA infections. For example, ceftriaxone is primarily used for more serious infections due to its broader spectrum but is not specifically indicated for minor MSSA infections. Clindamycin is effective against MSSA as well, but it is usually reserved for patients with penicillin allergies or when other agents are not appropriate. Tetracycline can be active against certain strains but is not typically a first-line choice for MSSA.

Thus, dicloxacillin is the preferred oral agent for addressing minor MSSA infections effectively.